Why Spectrum Pharmaceuticals Stock Soared in October
Spectrum Pharmaceuticals (NASDAQ: SPPI), a small-cap oncology company, saw its shares gain a whopping 39.2% in October, according to S&P Global Market Intelligence. The drugmaker's stock took flight after the company announced positive interim results from a midstage study assessing poziotinib in patients with EGFR-positive non-small cell lung cancer (NSCLC). Poziotinib's preliminary NSCLC data were presented at the World Conference on Lung Cancer in Japan in mid-October.
Image source: Getty Images.
Because lung cancer remains the most common malignancy in the world, poziotinib should be able to rack up several hundred million in annual sales even as a niche product (patients that express this particular subtype of NSCLC). And that's certainly a big deal for a company that's projected to generate only $131 million in revenue next year.
Source: Fool.com
Spectrum Pharmaceuticals Aktie
Derzeit ist die Community gegenüber der Spectrum Pharmaceuticals Aktie mit 0 Sell-Einschätzungen und 1 Buy-Einschätzungen noch unentschlossen.
Das Kursziel von 1 € für Spectrum Pharmaceuticals weist auf eine leichte Verbesserung gegenüber dem aktuellen Kurs von 0.95 € hin.
